"Becerra ("not a bodybuilder by any means at all, but I do like to look good with my shirt off") bought himself a powder labeled " retatrutide" online, mixed with water, then injected it into his muscles with a syringe, just as Weiss and other bodybuilders online described. For about a month, Becerra injected half a milligram a week. He was sold."
"Retatrutide is a GLP-1 drug, in the same family as Ozempic (semaglutide) and Mounjaro (tirzepatide). It was developed by the pharmaceutical giant Eli Lilly, and it is unique because it mimics three hunger hormones (GLP, GIP, and glucagon), while similar drugs on the market target one or two. In theory, that means more staggering weight-loss results and potentially other benefits."
"Here's the catch: Eli Lilly has not yet finished clinical trials on retatrutide. The earliest it could hit the market would be late 2026, though it's more likely to drop in 2027. It's widely regarded as a crucial piece in Eli Lilly's strategy for taking the lion's share of the world's $100 billion weight-loss drug industry."
A 24-year-old user self-administered powder labeled retatrutide after seeing bodybuilding posts claiming major fat-loss and preserved muscle. Retatrutide is a GLP-1 family drug developed by Eli Lilly that mimics GLP, GIP, and glucagon, potentially producing larger weight-loss effects and protecting lean muscle compared with single- or dual-agonist drugs. Early clinical results suggest outcomes comparable to bariatric surgery. Eli Lilly has not completed trials, and the drug is unlikely to reach the market before late 2026 or 2027 while the company positions it within a lucrative weight-loss market.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]